125 related articles for article (PubMed ID: 37730962)
1. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
Kridin K; Zirpel H; Mruwat N; Ludwig RJ; Thaci D
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2319-2326. PubMed ID: 37466275
[TBL] [Abstract][Full Text] [Related]
3. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
4. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
[TBL] [Abstract][Full Text] [Related]
5. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
[TBL] [Abstract][Full Text] [Related]
6. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
Kridin K; Schonmann Y; Solomon A; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
J Dermatolog Treat; 2022 Jun; 33(4):2014-2020. PubMed ID: 33759683
[TBL] [Abstract][Full Text] [Related]
7. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
[TBL] [Abstract][Full Text] [Related]
8. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
[TBL] [Abstract][Full Text] [Related]
9. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
10. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
Xie Y; Liu Y
Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
12. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry.
Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
J Am Acad Dermatol; 2022 Jan; 86(1):68-76. PubMed ID: 34256035
[TBL] [Abstract][Full Text] [Related]
13. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity.
Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
J Dermatolog Treat; 2022 Nov; 33(7):2975-2982. PubMed ID: 35737885
[TBL] [Abstract][Full Text] [Related]
14. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
[TBL] [Abstract][Full Text] [Related]
15. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.
Singla S; Putman M; Liew J; Gordon K
Lancet Rheumatol; 2023 Apr; 5(4):e200-e207. PubMed ID: 38251522
[TBL] [Abstract][Full Text] [Related]
16. Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients.
Ferrito M; Cincinelli G; Manara M; Di Taranto R; Favalli EG; Caporali R
Reumatismo; 2023 Jul; 75(2):. PubMed ID: 37462129
[TBL] [Abstract][Full Text] [Related]
17. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.
Kridin K; Schonmann Y; Damiani G; Peretz A; Onn E; Bitan DT; Cohen AD
Dermatol Ther; 2021 Jul; 34(4):e15003. PubMed ID: 34033207
[TBL] [Abstract][Full Text] [Related]
19. Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study.
Huang D; Yu Y; Lu J; Tan F; Shi Y
Front Med (Lausanne); 2023; 10():1280965. PubMed ID: 38020100
[TBL] [Abstract][Full Text] [Related]
20. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
